Menu
Close
Paxlovid is indicated for the treatment of COVID 19 in patients with 18 years of age and older who do not require supplemental oxygen and who are at high risk for progression to severe COVID 19. This medicinal product is under the conditional approval for emergency use of medicinal products for human use in emergency situation during a pandemic crisis*.
View the full PAXLOVIDTM leaflet, which includes dosing, clinical data, and safety information.
View the Package Leaflet, which contains important information for the patient about how to take PAXLOVIDTM and what to expect from treatment.
References: PAXLOVIDTM leaflet
This site is intended only for Thailand healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
Pfizer (Thailand) Ltd., 323 United center
building, Floor 36 and 37 Silom rd.,
Silom Bangrak, Bangkok 10500
Thailand Tel. 02-761-4555
These pages are not intended for patients or for members of the general public.
I confirm that I am a healthcare professional resident in Thailand
If you select 'No', you will be redirected to covid19oralrx.com where you will be able to access reference information on PAXLOVID™ (Nirmatrelvir/ritonavir)